Omega-3 Fatty Acids Therapy in Children with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial

Jańczyk, Wojciech; Lebensztejn, Dariusz Marek; Wierzbicka-Rucińska, Aldona; Mazur, Artur; Neuhoff-Murawska, Joanna; Matusik, Paweł; Socha, Piotr

doi:10.1016/j.jpeds.2015.01.056

Cited by 111 publications

(104 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We found a positive correlation between the n -6: n -3 PUFA ratio in cord blood and the AST:ALT ratio at age 6 years, suggestive of a protective effect of n -3 PUFAs on the liver, in accordance with previous studies showing a decrease in AST levels in children with nonalcoholic fatty liver disease after omega-3 fatty acid supplementation, as compared with placebo [13]. …”

Section: Discussion/conclusionsupporting

confidence: 90%

Body Composition and Circulating Polyunsaturated Fatty Acids at Age 6 Years: A Longitudinal Pilot Study

et al. 2018

View full text Add to dashboard Cite

Maternal polyunsaturated fatty acid (PUFA) status during pregnancy may influence birth outcomes and offspring adiposity during childhood. Cord blood PUFA levels associate positively with maternal PUFA and negatively with the newborn’s abdominal adiposity. However, longitudinal, prospective studies consistently evaluating maternal and cord blood and PUFA levels in childhood and their association with the child’s body composition are so far lacking. In a population of 16 apparently healthy children born appropriate for gestational age and followed longitudinally since birth, we assessed circulating PUFA (by gas chromatography) in maternal, cord, and peripheral blood at age 6 years and studied their correlation with body composition (by absorptiometry) and endocrine-metabolic variables at age 6 years. No associations were found among parameters of body composition and endocrine-metabolic variables at age 6 years and maternal, cord blood or circulating PUFA in peripheral blood. Maternal levels of n-6 linoleic acid, total n-6, and the ratio of n-6:n-3 correlated with their corresponding PUFA levels at age 6 years. In conclusion, in this pilot study, maternal, cord blood, and children’s circulating PUFA do not appear to have an impact on body composition and endocrine-metabolic status at the age of 6 years. The close association between maternal PUFA and offspring PUFA at that age may reflect a similarity in nutritional habits in the mother and child.

show abstract

Section: Discussion/conclusionsupporting

confidence: 90%

Body Composition and Circulating Polyunsaturated Fatty Acids at Age 6 Years: A Longitudinal Pilot Study

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In particular, despite certain favorable metabolic effects, fibrate monotherapy improves liver histology only to a minimal extent [186][187][188][189][190]. Similarly, PUFA supplementation may ameliorate some metabolic parameters and probably reduces liver fat content, but has no effect on liver inflammation and fibrosis [191][192][193][194][195][196].…”

Section: Fibrates and Polyunstaurated Famentioning

confidence: 99%

The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The limitation of this study was the exact confirmation of NAFLD, which was based on elevated alanine aminotransferase to more than 30% of the upper limit of normal and increased hepatic echogenicity on imaging such as sonography (31).…”

Section: Discussionmentioning

confidence: 96%

Treatment of Nonalcoholic Fatty Liver Disease in Children: A Systematic Review

Shahmirzadi

Barati

2017

J Pediatr Rev

View full text Add to dashboard Cite

Context: Nonalcoholic fatty liver disease (NAFLD) is a chronic liver illness that results from exceeding fat cumulating in the liver. NAFLD can result in progressive fibrosis, which leads to end-stage liver disease. It has rapidly evolved into the most common liver disease seen in the pediatric and adolescent population, being an increasingly common indication for liver transplant even in youths. Best practices in the management of pediatric NAFLD have not been clearly defined.Objectives: Due to increasing prevalence and the nature of the disease as well as importance of treatment plans and efficacy of each mode of treatment, all studies for pediatric fatty liver disease have been investigated for introducing definite or potential therapies. Data Sources:This systematic review aimed to include and analyze all studies descry the effectiveness of lifestyle modification, pharmacological, non-pharmacological, and dietary supplement treatments in children suffered from fatty liver, NAFLD, or NASH. The PUBMED/MEDLINE for Controlled Trials, Scopus, and OVID databases were searched for articles published up to and including December 2016.Study Selection, Data Extraction: All study in the pediatric group with diagnosis of fatty liver spectrum were included in this review. Adult studies were excluded. The results extracted and expanded.Results: A total of 27 randomized controlled trials were identified after the complete search, deletion of duplicates, removal of irrelevant studies, and final assessment of studies. Treatment plans of interest in these pediatrics articles included: lifestyle modifications, fish oil, and omega-3 fatty acids, including docosahexaenoic acid (DHA), probiotics, vitamin E, metformin, ursodeoxycholic acid, vitamin D, and bariatric surgery. Conclusions:Lifestyle modification is the only approved treatment modality for which evidence-based studies have documented benefits. Omega-3 fatty acids, particularly DHA, are probably effective. Probiotics likely have therapeutic effects in cases of fatty liver; however, further research is needed. Vitamin E and metformin have equivocal results. Ursodeoxycholic acid is recommended as an adjuvant; however, the data are insufficient for vitamin D. Bariatric surgery is not an acceptable plan in pediatric patients. Research of fatty liver diseases in children in all aspects of treatments is urgently needed.

show abstract

Omega-3 Fatty Acids Therapy in Children with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial

Cited by 111 publications

References 23 publications

Body Composition and Circulating Polyunsaturated Fatty Acids at Age 6 Years: A Longitudinal Pilot Study

Body Composition and Circulating Polyunsaturated Fatty Acids at Age 6 Years: A Longitudinal Pilot Study

The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans

Treatment of Nonalcoholic Fatty Liver Disease in Children: A Systematic Review

Contact Info

Product

Resources

About